Creyon Bio Secures $13M Series A Funding — Pioneering On-Demand Oligonucleotide Therapeutics and Reinventing Drug Development

We are excited to announce that Creyon Bio, a transformative force in the biotechnology arena, has successfully raised $13,000,000 in its latest funding round. This significant capital infusion is a strong endorsement of the company’s innovative vision to reinvent drug development from the ground up. With a focus on making on-demand oligonucleotide therapeutics possible, Creyon Bio is setting a new standard in personalized medicine and redefining the landscape of treatment options available to patients worldwide. This funding milestone will enable Creyon Bio to expand its research and development initiatives, driving forward breakthrough innovations in oligonucleotide technology. The company plans to leverage these resources to accelerate the refinement of its proprietary platform, optimize manufacturing processes, and broaden its therapeutic portfolio to address a range of unmet medical needs. By investing in advanced technologies and boosting its strategic partnerships, Creyon Bio is poised to shorten the drug development timeline and bring safer, more effective treatments to market at an unprecedented pace. Moreover, the new capital will support the expansion of the company's team of world-class scientists, engineers, and clinical experts, ensuring that it remains at the forefront of personalized medicine breakthroughs. As the company continues to push the boundaries of what is possible in rapid therapeutic development, this funding round also reinforces the confidence of investors in Creyon Bio’s capability to revolutionize the pharmaceutical industry. With its groundbreaking approach and commitment to innovation, Creyon Bio is not only transforming drug development but also empowering a future where tailored healthcare solutions become the norm.